Clinical trials: Lymphoid Neoplasms
Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer
Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia
Evaluation of safety profile and tolerability of MabThera (rituximab) in combination with chemotherapy (fludarabine and cyclophosphamide) in the treatment of Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT02461316
- Testing
- No intervention
- Where
- 3 sites in Serbia
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Acute Lymphoblastic Leukemia
A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia
This study is for a population of patients with few or no alternative options that was conducted to determine the response rate to clofarabine.
- Trial name
- NCT00930098
- Testing
- clofarabine
- Where
- 36 sites in Austria, France and 4 more
- Volunteers
- 74 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Lymphocytic Leukemia
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of venetoclax (GDC-0199, ABT-199) administered in combination with bendamustine and rituximab (BR) (MabThera/Rituxan) or bendamustine…
- Trial name
- NCT01671904
- Testing
- Bendamustine, Obinutuzumab, Rituximab
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 84 people
- Sponsor
- Genentech, Inc.
Graft Versus Host Disease, Leukemia
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may reduce the chance of developing graft-versus-host disease following bone marrow transplantation.
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00004255
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- 15 sites in United States
- Sponsor
- Chimeric Therapies
B-cell Lymphoid Malignancies
A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
This is a phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK (pharmacokinetics), and preliminary efficacy and to establish the…
- Trial name
- NCT05822843
- Testing
- ESG206
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive hematologic malignancies.
- Trial name
- NCT07312630
- Testing
- LV009 Injection Infusion
- Where
- China
- Volunteers
- 19 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p…
- Trial name
- NCT02966756
- Testing
- Venetoclax
- Where
- 31 sites in Australia, China and 2 more
- Volunteers
- 66 people
- Sponsor
- AbbVie
Lymphoma, Malignant, Non-hodgkin Lymphoma
DS-3201b in Participants With Lymphomas
DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to…
- Trial name
- NCT02732275
- Testing
- DS-3201b
- Where
- 20 sites in United States, Japan
- Volunteers
- 100 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Leukemia, Lymphoma
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as fludarabine and pixantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00551239
- Testing
- rituximab, fludarabine phosphate, pixantrone dimaleate
- Where
- United States
- Sponsor
- CTI BioPharma
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL
Asparaginase (Asp) is used during the induction phase of ALL treatment for children and young adults. Its efficacy is counterbalanced by its toxicity, mainly in patients 40 years or older.
- Trial name
- NCT01910428
- Testing
- L-asparaginase encapsulated in RBC
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- ERYtech Pharma
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
- Trial name
- ALLight (NCT07109219)
- Testing
- AZD4512 monotherapy
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 83 people
- Sponsor
- AstraZeneca
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
This study will evaluate the efficacy and safety of duvelisib in combination with bendamustine and rituximab (DBR) vs placebo in combination with bendamustine and rituximab (PBR) in subjects with previously-treated indolent…
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT02576275
- Testing
- Duvelisib, Rituximab, Bendamustine
- Where
- 7 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- SecuraBio
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
This study will assess the pharmacokinetics of nilotinib in Ph+ CML pediatric patients that are newly diagnosed or resistant or intolerant to imatinib or dasatinib or refractory or relapsed Ph+ ALL compared to the adult…
- Trial name
- NCT01077544
- Testing
- Nilotinib
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
This study primarily determined the safety and tolerability of escalating doses of vosaroxin (SNS-595) in 2 dose schedules, and assessed the PK profile of vosaroxin and defined a recommended dose regimen for Phase 2 studies.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
- Trial name
- NCT00246662
- Testing
- Vosaroxin
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Sunesis Pharmaceuticals
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia
- Trial name
- NCT04013685
- Testing
- Orca-T
- Where
- 21 sites in United States
- Volunteers
- 155 people
- Sponsor
- Orca Biosystems, Inc.
ALL, Adult, AML, Adult
A Study of BN104 in the Treatment of Acute Leukemia
The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken once daily or twice daily in patients with acute lymphocytic leukemia or acute myeloblastic leukemia.
- Conditions
- ALL, Adult, AML, Adult, Acute Leukaemia, KMT2A Rearrangement
- Trial name
- NCT06052813
- Testing
- BN104 monotherapy, BN104 monotherapy - rp2d
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)
Chronic Lymphocytic Leukemia
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
- Trial name
- ALICIA(BY) (NCT07288515)
- Where
- 4 sites in Belarus
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
This study will evaluate a gene expression signature (Growth Factor Signature [GFS]) as a biomarker for response/resistance to BRC-ABL oncogene inhibitors.
- Trial name
- NCT00860535
- Testing
- Comparator: Biomarker evaluation
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
An open-label phase 1 study to assess safety and efficacy of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Blast-phase Chronic Myelogenous Leukemia, AML
- Trial name
- NCT00964873
- Testing
- STA-9090 (ganetespib)
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Synta Pharmaceuticals Corp.
ALL, Adult
COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being
The aim of this research is to collect dietary intake, physical activity, mood and stress data during and after the Illinois shelter-in-place and social distancing orders for the COVID-19 pandemic.
- Trial name
- CoVS (NCT04357041)
- Where
- United States
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.